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Major depressive disorder (MDD) is a common disorder that represents a leading cause of disability in the 
world. It is thought originate from the interaction between susceptibility genes and environmental events, 
such as stress, to which an individual can be exposed in different moments of life. One of the major problems 
of depression is the relevant percentage of patients who do not show an adequate response to 
antidepressant therapy, as well as the high rate of relapse. Growing evidence suggest that the activation of 
the inflammatory/immune system contributes to the pathogenesis of depression. In particular, depression 
shows elevated comorbidity with cancer, arthritis rheumatoid, cardiovascular and neurodegenerative 
disease, characterized by inflammatory alteration. In addition, elevated blood levels of the pro-inflammatory 
cytokines including interleukin (IL)-1b, interleukin (IL)-6 and tumor necrosis factor (TNF)-a are commonly 
found in depressed patient.  
On these bases, it is important to characterize the changes of immune/inflammatory response in animal 
models of depression in order to establish their relationship with the depressive phenotype as well as the 
involvement in antidepressant response. 
Accordingly, the first aim of this study was to evaluate the inflammatory response of rats exposed to a chronic 
mild stress (CMS) paradigm, which represents a well-established animal model of depression. Next, a group 
of animals was treated with the antidepressant imipramine or the antipsychotic drug lurasidone, in order to 
evaluate the ability of the treatment to interfere with inflammatory alterations produced by the stress 
procedure. 
 
 
 
 
